Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of JYP0061 in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• JYP0061

Snippet

Sponsor: Guangzhou JOYO Pharma Co., Ltd | Conditions: Neuromyelitis Optica Spectrum Disorders | Phase 2 | Status: RECRUITING